NICE CKS—constipation in adults
This summary has been developed for use by community pharmacists under our Guidelines for Pharmacy title, it therefore only covers the information relevant to this setting, and is deliberately concise. Areas covered in the summary include: advice for those with the condition, management (short-duration and chronic), secondary causes of the ...
Dealing with chronic constipation—information for GPs
This summary highlights the results of research on constipation and treatment options and combines them into a simple diagram to help guide and provide a best practice pathway for general practice in its recognition, treatment, and point of escalation for the available therapies for chronic constipation. For further information, please ...
COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response
The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID-19 pandemic.
NICE CKS—diarrhoea
This summary has been developed for use by community pharmacists under our Guidelines for Pharmacy title and therefore only covers the information relevant to this setting. For community pharmacists, the referral section implies primary care referral prior to secondary care referral. Please see the full guideline for the complete set ...
NICE GORD in children guideline
A useful NICE guideline summary on the recognition, diagnosis, and management of GORD in children and young people.
Educational resources
Opioid-induced constipation: optimal management and the role of PAMORA drugs
This webinar has been initiated and commissioned by Sandoz Ltd and organised in partnership with Guidelines. Sandoz Ltd has reviewed the scope of the webinar, commissioned the speakers, and approved all materials related to the webinar. The speakers have been paid an honorarium. The views and opinions of the speakers ...
Pancreatic exocrine insufficiency guideline
This management algorithm was developed by a multidisciplinary expert panel: Hambling C et al with the support of a grant from Mylan Ltd.